康泰生物(300601.SZ):吸附破傷風疫苗開啟Ⅰ期臨牀試驗
格隆匯3月1日丨康泰生物(300601.SZ)公佈,公司全資子公司北京民海生物科技有限公司(以下簡稱“民海生物”)研發的吸附破傷風疫苗已完成Ⅰ期臨牀試驗準備工作,正式開啟Ⅰ期臨牀試驗,並於今日成功完成首例受試者入組。
吸附破傷風疫苗是採用破傷風類毒素經佐劑吸附製備的疫苗。該疫苗適用於發生創傷機會較多的人羣,妊娠期婦女接種本品可預防產婦及新生兒破傷風。接種本疫苗後可刺激機體產生破傷風抗體,預防破傷風。破傷風是一種由破傷風梭狀芽孢桿菌經皮膚或黏膜傷口侵入人體後,在傷口局部生長繁殖併產生毒素導致的極其嚴重的急性感染性疾病。目前接種破傷風疫苗是預防破傷風最經濟和有效的措施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.